OncoSec Medical Incorporated is a clinical-stage biotechnology company. The Company is focused on developing intratumoral immunotherapies to stimulate the patientâ€™s immune system to target cancer cells and eradicate disease. Its lead immunotherapy investigational product candidate-TAVO (tavokinogene telseplasmid)-enables the intratumoral delivery of DNA-based interleukin 12 (IL-12), a naturally occurring protein with immune-stimulating functions. The therapeutic approach TAVO-EP, which employs electroporation, is designed to produce a localized expression of IL-12 in the tumor microenvironment and, thereby, stimulate the immune system to target and attack tumors.

Employees

Sector

Biotechnology & Medical Research

More about the company

23-08-09	Motion for Asset Sale Approved for OncoSec Medical Incorporated	CI
23-07-28	Motion for Asset Sale Filed by OncoSec Medical Incorporated	CI

Market Cap	243K 210K 197K 179K 337K 23.23M 342K 2.31M 904K 11.64M 912K 892K 38.72M	P/E 2021	-1.59x	P/E 2022	-0.83x
Enterprise Value	-882K -761K -714K -651K -1.22M -84.33M -1.24M -8.37M -3.28M -42.25M -3.31M -3.24M -141M	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

23-08-09	Motion for Asset Sale Approved for OncoSec Medical Incorporated	CI
23-07-28	Motion for Asset Sale Filed by OncoSec Medical Incorporated	CI
23-06-28	OncoSec Medical Incorporated(NasdaqCM:ONCS) dropped from S&P TMI Index	CI
23-06-23	Wall Street Set to Open Lower Ahead of June's Flash PMI; Oil Prices Drop Sharply	MT
23-06-23	US Futures Trend Lower Premarket Friday Ahead of June's Flash PMI	MT
23-06-23	Top Premarket Gainers	MT
23-06-23	OncoSec Medical Incorporated(OTCPK:ONCS.Q) dropped from NASDAQ Composite Index	CI
23-06-17	Certain Stock Options of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	CI
23-06-17	Certain Common Stock of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	CI
23-06-17	Certain Promissory Notes of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	CI
23-06-17	Certain Warrants of OncoSec Medical Incorporated are subject to a Lock-Up Agreement Ending on 18-JUN-2023.	CI
23-06-14	OncoSec Medical Incorporated Announces Resignation of Dr. Robert Arch as Chief Executive Officer	CI
23-06-14	OncoSec Medical Incorporated Announces Management Resignations	CI

22-11-14	BTIG Downgrades OncoSec Medical to Neutral From Buy	MT
22-03-16	BTIG Adjusts OncoSec Medical's Price Target to $5 From $10, Reiterates Buy Rating	MT
21-03-08	OncoSec Medical Incorporated : BTIG Initiates OncoSec Medical at Buy With $10 Price Target	MT

23-06-14	OncoSec Medical Incorporated : Bankruptcy - Form 8-K	PU
23-06-02	ONCOSEC MEDICAL INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
23-05-18	OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
23-05-16	OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
23-05-16	OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program	PR

OncoSec Medical Inc Stock OTC Bulletin Board

Stocks

ONCS

US68234L1089

Biotechnology & Medical Research

Valuation: OncoSec Medical Inc

Latest news : OncoSec Medical Inc

Analysts' recommendations: OncoSec Medical Inc

Press Releases: OncoSec Medical Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.68%	-2.28%	+1.91%	+19.70%	48.42B
REVOLUTION MEDICINES, INC.	+4.56%	+2.77%	+483.54%	+626.19%	43.66B
BEONE MEDICINES AG	+4.33%	+0.89%	+13.43%	+88.37%	39.51B
IQVIA HOLDINGS INC.	+1.98%	-0.14%	+25.51%	+12.81%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+58.18%	32.61B
ASCENDIS PHARMA A/S	-0.09%	-2.80%	-	-	16.32B
MEDPACE HOLDINGS, INC.	+2.32%	-1.65%	+27.99%	+133.64%	16.15B
EUROFINS SCIENTIFIC SE	-0.62%	-0.06%	+3.95%	+27.74%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.89%	+3.12%	+81.96%	+42.91%	13.37B
Average	+1.61%	-0.35%	+82.36%	+126.19%	29.24B
Weighted average by Cap.	+1.95%	-0.62%	+101.30%	+151.14%

	2021	2022
Net sales	-	-
Net income	-45.17M -38.99M -36.58M -33.32M -62.65M -4.32B -63.52M -429M -168M -2.16B -170M -166M -7.2B	-34.18M -29.51M -27.68M -25.21M -47.41M -3.27B -48.07M -325M -127M -1.64B -128M -126M -5.45B
Net Debt	-33.63M -29.04M -27.24M -24.81M -46.65M -3.22B -47.3M -319M -125M -1.61B -126M -124M -5.36B	-1.12M -971K -911K -830K -1.56M -108M -1.58M -10.68M -4.19M -53.89M -4.22M -4.13M -179M

End-of-day quote OTC Bulletin Board
- ^USD	-